Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial

Inclusion Criteria:

- Subjects must have received Lambda in a previous trial and have Hepatitis C virus
(HCV) Ribonucleic acid (RNA) < LOQ at the completion of the required post-treatment
follow-up (must enter this study within 6 months of completion of the required
post-treatment follow-up in the previous trial) NOTE: For blinded parent trials,
subjects who have HCV RNA follow-up may enter this study without knowledge of their treatment assignment in the
parent study. Subjects who received control agents (eg, pegylated-interferon alfa) in
the previous protocol will be allowed to participate until unblinded treatment
information is released; at that time subjects will have the option to continue in
the study

Exclusion Criteria:

- Subjects must not have been treated with any antiviral or immunomodulatory drug for
chronic hepatitis C after completion of the previous study of Lambda